Abionyx Pharma (LTS:0RAG) ROCE % : -26.55% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abionyx Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -26.55%.

Abionyx Pharma ROCE % Historical Data

The historical data trend for Abionyx Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma ROCE % Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

39.24

-28.00

-53.40

-32.11

-32.34

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-67.66	-36.96	-27.66	-47.50	-26.55

Abionyx Pharma ROCE % Calculation

Abionyx Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.499	/	( ( (15.823 - 5.094)	+	(14.834 - 3.925) )	/ 2 )
	=	-3.499	/	( (10.729	+	10.909)	/ 2 )
	=	-3.499	/	10.819
	=	-32.34 %

Abionyx Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.524	/	( ( (13.832 - 5.725)	+	(14.834 - 3.925) )	/ 2 )
	=	-2.524	/	( ( 8.107	+	10.909 )	/ 2 )
	=	-2.524	/	9.508
	=	-26.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Abionyx Pharma (LTS:0RAG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abionyx Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (LTS:0RAG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (LTS:0RAG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ABNX:France 609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (LTS:0RAG) Headlines

No Headlines